

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC  
Form 8-K  
May 26, 2004

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 25, 2004  
-----

Progenics Pharmaceuticals, Inc.  
-----

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of incorporation)	000-23143 ----- (Commission File Number)	13-3379479 ----- (IRS Employer Identification No.)
--	---	---

777 Old Saw Mill River Road, Tarrytown, New York ----- (Address of principal executive offices)	10591 ----- (Zip Code)
---	------------------------------

Registrant's telephone number, including area code (914) 789-2800  
-----

-----  
(Former name or former address, if changed since last report.)

Item 7. Financial Statements and Exhibits

(c) Exhibits

Exhibit 99.1	Description Press Release dated May 25, 2004 (filed herewith).
--------------	---

Item 9. Regulation FD Disclosure.

## Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

On May 25, 2004, Progenics Pharmaceuticals, Inc. issued a press release announcing the completion of two phase 1 clinical trials of oral formulations of its investigational drug methyl naltrexone (MNTX) conducted utilizing 61 healthy volunteers. Preliminary analysis of the data from such trials of three dose levels of either an immediate-release or enteric coated formulation of MNTX indicated that the drug was well tolerated and exhibited predictable pharmacokinetics. A copy of the press release is attached as Exhibit 99.1.

The information furnished pursuant to Item 9 in this Form 8-K shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no duty or obligation to publicly update or revise the information furnished pursuant to Item 9 in this Form 8-K.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ PHILIP K. YACHMETZ

-----  
Philip K. Yachmetz  
Vice President, General Counsel and Secretary

Date: May 25, 2004